Literature DB >> 7534783

Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium.

J A Nagy, D R Senger, H F Dvorak, A M Dvorak.   

Abstract

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) is a cytokine secreted by many animal and human tumors, activated macrophages, keratinocytes, rheumatoid synovial cells, embryonic tissues, and by cultured epithelial and mesenchymal cell lines. It acts selectively on vascular endothelial cells to increase their permeability to circulating macromolecules and to stimulate their replication. Although not detectably expressed by vascular cells in the human and animal tumors we have studied, VPF/VEGF accumulates in the microvessels supplying tumors and certain inflammatory reactions in which VPF/VEGF is also overexpressed. Light microscopic immunohistochemistry lacked the resolution necessary to localize VPF/VEGF precisely in such vessels. Therefore, we used a pre-embedding immunocytochemical method to localize VPF/VEGF at the ultrastructural level in the new blood vessels that are elicited in the peritoneal walls of mice bearing a transplantable mouse ascites tumor of ovarian origin. Intense immunostaining for VPF/VEGF was observed on the abluminal plasma membrane of tumor-associated microvascular endothelial cells and in vesiculovacuolar organelles (VVOs) present in these same endothelial cells. (VVOs are recently described cytoplasmic organelles present in tumor vascular endothelium that provide an important pathway for extravasation of circulating macromolecules.) In contrast to labeling of the abluminal plasma membrane and VVO vesicles and vacuoles, endothelial cytoplasmic organelles, such as multivesicular bodies and Weibel-Palade bodies, and the underlying basal lamina, did not stain with antibodies to VPF/VEGF. The distribution of VPF/VEGF here described corresponds to that anticipated for high-affinity VFP/VEGF receptors, although binding of VPF/VEGF to other endothelial cell surface structures, such as plasma membrane proteoglycans, is also a possibility.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534783     DOI: 10.1177/43.4.7534783

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  17 in total

Review 1.  What, if anything, is an angiogenic factor?

Authors:  W Risau
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 2.  Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy.

Authors:  G Molema; L F de Leij; D K Meijer
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

3.  Vascular morphogenesis and remodeling in a human tumor xenograft: blood vessel formation and growth after ovariectomy and tumor implantation.

Authors:  S Patan; S Tanda; S Roberge; R C Jones; R K Jain; L L Munn
Journal:  Circ Res       Date:  2001-10-12       Impact factor: 17.367

Review 4.  Normalization of the vasculature for treatment of cancer and other diseases.

Authors:  Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

Review 5.  Cellular mechanisms of blood-retinal barrier dysfunction in macular edema.

Authors:  S A Vinores; N L Derevjanik; H Ozaki; N Okamoto; P A Campochiaro
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

6.  VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain.

Authors:  Z G Zhang; L Zhang; Q Jiang; R Zhang; K Davies; C Powers; N v Bruggen; M Chopp
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

7.  Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.

Authors:  G Thurston; J W McLean; M Rizen; P Baluk; A Haskell; T J Murphy; D Hanahan; D M McDonald
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

8.  Treatment of hemangioma by transfection of antisense VEGF gene.

Authors:  Shengguo Shan; Guang Shan; Duanlian Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

9.  A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

10.  Effects of Surface Charge, PEGylation and Functionalization with Dipalmitoylphosphatidyldiglycerol on Liposome-Cell Interactions and Local Drug Delivery to Solid Tumors via Thermosensitive Liposomes.

Authors:  Matteo Petrini; Wouter J M Lokerse; Agnieszka Mach; Martin Hossann; Olivia M Merkel; Lars H Lindner
Journal:  Int J Nanomedicine       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.